Aurobindo Pharma Limited (NSE:AUROPHARMA)

Market Cap	695.28B
Revenue (ttm)	309.22B
Net Income (ttm)	34.91B
Shares Out	580.80M
EPS (ttm)	59.81
PE Ratio	20.01
Forward PE	16.44
Dividend	3.00 (0.25%)
Ex-Dividend Date	n/a

Volume	878,977
Average Volume	1,845,479
Open	1,187.40
Previous Close	1,210.10
Day's Range	1,186.50 - 1,217.00
52-Week Range	1,010.00 - 1,592.00
Beta	0.25
RSI	53.89
Earnings Date	May 28, 2025

About Aurobindo Pharma

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Employees: 26,015
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AUROPHARMA

Financial Performance

In 2023, Aurobindo Pharma's revenue was 290.02 billion, an increase of 16.68% compared to the previous year's 248.55 billion. Earnings were 31.73 billion, an increase of 64.62%.